Notably, the original ATG/TLI study showed a significant OS and event-free survival benefit in NHL patients proceeding to alloHCT with CR or partial response compared to stable or progressive disease [[7]]. In preclinical models, anti-thymocyte globulin plus total lymphoid irradiation (ATG/TLI) conditioning alters the host T-cell profile to favor invariant natural killer T-cells that suppress graft-vs-host disease (GVHD) while preserving GVL activity [[4]]. The investigators showed ATG/TLI to have a lower 2-year incidence of chronic GVHD with similar OS, but a higher relapse rate, 50% with ATG/TLI vs 22% with Flu plus 2 Gy TBI. [Extracted from the article]